期刊
FUTURE ONCOLOGY
卷 13, 期 4, 页码 357-368出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2016-0261
关键词
genomics; immunotherapy; novel therapy; orphan disease; osteosarcoma; outcome; pediatrics; sarcoma; targeted therapy
类别
High-grade osteosarcomas are the most common primary malignant tumors of bone. With complete surgical resection and multi-agent chemotherapy up to 70% of patients with high-grade osteosarcomas and localized extremity tumors can become long-term survivors. The prognosis, however, is poor for patients with nonresectable, primary metastatic or relapsed disease. Outcome is essentially unchanged for three decades. Herein, we describe selected novel insights into the genomics, biology and immunology of the disease and discuss selected strategies, which hold promise to overcome the current stagnation in the therapeutic success in childhood osteosarcoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据